Skip to content
Screener

Arcutis Biotherapeutics, Inc. ARQT EV / EBITDA

EV / EBITDA at other companies

Pfizer logo
PfizerPFE
12.9×—
Amgen logo
AmgenAMGN
15.7×+0.7×
Incyte logo
IncyteINCY
10×+1.0×
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
7.9×—
Rigel Pharmaceuticals logo
Rigel PharmaceuticalsRIGL
4.3×-1.7×
Journey Medical Corporation logo
Journey Medical CorporationDERM
19.9×—

Other financials

Income statement

See full
Revenue$129.9M+59.3%
Gross profit$118.9M+60.7%
Operating income$16.4M+212%
Net income$15.0M+194%
EPS (diluted)$0.11+185%

Balance sheet

See full
Cash & equivalents$34.4M-52.9%
Total debt$114.1M+3.6%
Total equity$220.6M+58.7%
Total assets$488.5M+38.6%

Cash flow

See full
Operating cash flow$12.6M—
CapEx$158.0K+103%
Free cash flow$12.5M—

Valuation

See full
Market cap$3.32B+81.4%
Enterprise value$3.4B+82.1%
P/S7.2×+0.2×

Profitability

See full
Gross margin91.1%+2.0pp
Operating margin-12%-5.7pp
Net margin-13.9%-6.6pp
FCF margin-52.5%-21.9pp

Returns & leverage

See full
Return on equity-28.2%-13.0pp
Debt / equity0.5×-0.3×
Current ratio2.9×-0.3×

Where this comes from

Calculated from Arcutis Biotherapeutics, Inc.’s reported figures.

enterprise value/ebitda=125.8×

Based on the most recent quarter.

The source filing: Arcutis Biotherapeutics, Inc.’s 10-Q, filed August 6, 2025. Open the filing →

Filed
Aug 6, 2025
Fiscal quarter
Q2 FY2025
Calendar quarter
Q2 2025
Accession
0001787306-25-000124

FAQ

What is Arcutis Biotherapeutics, Inc.'s EV / EBITDA?
Arcutis Biotherapeutics, Inc. (ARQT) reported EV / EBITDA of 125.8× in Q2 2024.
What does EV / EBITDA mean?
Enterprise value (market cap plus total debt minus cash) at the quarter end divided by trailing-twelve-month EBITDA. A capital-structure-neutral valuation multiple.

Ask your AI about Arcutis Biotherapeutics, Inc.'s ev / ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude